Acknowledgement and Consent for Disclosure of Potential Conflict(s) of Interest and Waivers under 18 U.S.C. §208(b)(3) and 21 U.S.C. §355 (n)(4)

Mr. Marshall Loeb

Committee: The Peripheral and Central Nervous System Drugs Advisory Committee

Meeting Date: May 17, 2006

I acknowledge that contingent upon public disclosure of the financial interest listed below, related to agenda item concerning the discussion of supplemental new drug application (NDA) 20823, SE1-016, Exelon® (rivastigmine tartarte) Capsules (1.5 milligrams (mg), 3.0 mg, 4.5 mg, and 6.0 mg), sponsored by Novartis Pharmaceuticals Corporation, a subsidiary of Novartis AG, for the proposed indication of the treatment of mild to moderate dementia associated with Parkinson's disease. Novartis Farmaceutica S.A. (Spain) manufactures the capsules and Novartis Pharmaceuticals Corporation distributes the product, I am eligible to receive waivers under 18 U.S.C. §208(b)(3).
and 21 U.S.C. §355 (n)(4).

Type of Interest	Nature	Magnitude
Stock	Competing Firm	Value between $50,001 to $100,000.

I hereby request that FDA make this information publicly available on my behalf. I understand that without public disclosure of the interest, the waiver is not valid.

/s/ 04/04/06

Signature of SGE Date